Ocular Therapeutix, Inc (OCUL) Files Form 4 Insider Buying : Amarpreet Sawhney Buys 10,000 Shares

Ocular Therapeutix, Inc (OCUL): Amarpreet Sawhney , CEO of Ocular Therapeutix, Inc purchased 10,000 shares on Jun 9, 2016. The Insider buying transaction was reported by the company on Jun 10, 2016 to the Securities and Exchange Commission. The shares were purchased at $6.70 per share for a total value of $67,000.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Nov 18, 2015, Amarpreet Sawhney (CEO) purchased 10,000 shares at $8.25 per share price.On Sep 17, 2015, James Fortune (Chief Operating Officer) sold 9,470 shares at $17.16 per share price.Also, On Jun 15, 2015, Charles M Warden (director 10% owner) sold 320,000 shares at $22.00 per share price.On Mar 6, 2015, Eric Ankerud (officer ) purchased 1,000 shares at $13.00 per share price.

Shares of Ocular Therapeutix Inc (OCUL) ended Thursday, Jun 9, 2016 session in red amid volatile trading. The shares closed down -0.27 points or -3.97% at $6.53 with 3,40,286 shares getting traded. Post opening the session at $6.81, the shares hit an intraday low of $6.51 and an intraday high of $6.83 and the price vacillated in this range throughout the day. The company has a market cap of $162 M and the number of outstanding shares has been calculated to be 2,47,66,409 shares. The 52-week high of Ocular Therapeutix Inc is $29.22 and the 52-week low is $5.07.

Ocular Therapeutix Inc Money Flow Index Chart

Ocular Therapeutix Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG) which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development such as OTX-DP OTX-TP OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP.

Leave a Reply

Ocular Therapeutix Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Ocular Therapeutix Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.